- Home
- CGO vs ATOS Comparison
CGO vs ATOS Comparison
Compare CGO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- ATOS
- Stock Information
- Founded
- CGO 2004
- ATOS 2009
- Country
- CGO United States
- ATOS United States
- Employees
- CGO N/A
- ATOS N/A
- Industry
- CGO Investment Managers
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- CGO Finance
- ATOS Health Care
- Exchange
- CGO Nasdaq
- ATOS Nasdaq
- Market Cap
- CGO 105.3M
- ATOS 96.8M
- IPO Year
- CGO N/A
- ATOS 2012
- Fundamental
- Price
- CGO $9.82
- ATOS $0.62
- Analyst Decision
- CGO
- ATOS Strong Buy
- Analyst Count
- CGO 0
- ATOS 3
- Target Price
- CGO N/A
- ATOS $7.00
- AVG Volume (30 Days)
- CGO 34.7K
- ATOS 699.0K
- Earning Date
- CGO 01-01-0001
- ATOS 05-12-2025
- Dividend Yield
- CGO 9.25%
- ATOS N/A
- EPS Growth
- CGO N/A
- ATOS N/A
- EPS
- CGO N/A
- ATOS N/A
- Revenue
- CGO N/A
- ATOS N/A
- Revenue This Year
- CGO N/A
- ATOS N/A
- Revenue Next Year
- CGO N/A
- ATOS N/A
- P/E Ratio
- CGO N/A
- ATOS N/A
- Revenue Growth
- CGO N/A
- ATOS N/A
- 52 Week Low
- CGO $7.90
- ATOS $0.55
- 52 Week High
- CGO $10.93
- ATOS $1.81
- Technical
- Relative Strength Index (RSI)
- CGO 44.33
- ATOS 42.51
- Support Level
- CGO $9.70
- ATOS $0.56
- Resistance Level
- CGO $10.20
- ATOS $0.67
- Average True Range (ATR)
- CGO 0.40
- ATOS 0.06
- MACD
- CGO 0.04
- ATOS 0.00
- Stochastic Oscillator
- CGO 64.16
- ATOS 43.75
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.